Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study James PhillipsAugust 19, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 James PhillipsAugust 6, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury James PhillipsAugust 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) James PhillipsJuly 21, 2026
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders James PhillipsMay 11, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 James PhillipsMay 7, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board James PhillipsApril 6, 2026
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study James PhillipsMarch 30, 2026
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference James PhillipsMarch 24, 2026
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference James PhillipsMarch 19, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 James PhillipsFebruary 26, 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 James PhillipsJanuary 26, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds James PhillipsJanuary 23, 2026
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI James PhillipsJanuary 21, 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) James PhillipsJanuary 14, 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) James PhillipsJanuary 12, 2026
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development James PhillipsJanuary 7, 2026
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting James PhillipsDecember 1, 2025
